Review articles
 

By Dr. Uros Bele , Dr. Tine Hajdinjak
Corresponding Author Dr. Uros Bele
Division of Urology, Department of Surgery, Murska Sobota General Hospital, - Slovenia SI-9001
Submitting Author Dr. Uros Bele
Other Authors Dr. Tine Hajdinjak
Division of Urology, Department of Surgery, Murska Sobota General Hospital, - Slovenia

UROLOGY

Urolithiasis, Kidney stone formation, Oxalate, Hyperoxaluria, Oxalate degrading bacteria, Oxalobacter formigenes

Bele U, Hajdinjak T. The Role of Oxalate in Urolithiasis. WebmedCentral UROLOGY 2012;3(1):WMC002877
doi: 10.9754/journal.wmc.2012.002877

This is an open-access article distributed under the terms of the Creative Commons Attribution License(CC-BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
No
Submitted on: 11 Jan 2012 09:08:53 PM GMT
Published on: 12 Jan 2012 07:34:11 AM GMT

Abstract


Urolithiasis is a frequent urological condition and oxalate plays an important role in kidney stone formation. Since hyperoxaluria seems to be one of the main risk factors for developing recurrent kidney stones and progressive nephrocalcinosis, many researches are focused on lowering the urinary oxalate. For now, treatment of hyperoxaluria consists of dietary oxalate restrictions and/or therapeutic drug treatment. These are rather limited options and a sufficient reduction in urinary oxalate is not always achieved. In this review, oxalate absorption, its excretion, hyperoxaluria, as well as some treatment options for hyperoxaluria will be discussed.
Keywords: Urolithiasis, Kidney stone formation, Oxalate, Hyperoxaluria, Oxalate degrading bacteria, Oxalobacter for migenes.

Introduction


Urolithiasis is a frequent urological condition. The incidence for developing urolithiasis in Europe and USA is estimated at 0,5% per year, whereas the prevalence is estimated around 5,2% of the population per year (1,2). It has been proposed that calcium oxalate composites approximately 80% of all kidney stones (3). Intestinal absorption of dietary oxalate and renal handling of it are believed to be risk factors for calcium oxalate stone formation, which implies the very important role of oxalate in the formation of kidney stones (4).
Despite the fact that urinary stones can form anywhere in the urinary tract between the kidney and the bladder, the majority of the stones in the western cultures are formed in the kidneys. The biochemical processes involved in stone formation are (a) supersaturation, (b) crystallization, (c) crystal nucleation, (d) crystal retention, (e) formation of stone nidus and (f) finally development of stone (5). Supersaturation of the urine with calcium oxalate creates a perfect environment for crystallization. We need to understand that the urinary calcium oxalate supersaturation, and consequently crystallization, not only depends on urinary calcium and oxalate concentrations, but is also influenced by several other factors: (a) the presence of low molecular weight compounds, such as magnesium, citrate, pyrophosphate and bisphosphonate, (b) presence of high molecular weight compounds, such as glycosaminoglycans and proteins, (c) lipids and cellular membranes. These form complexes with calcium and oxalate and as a consequence act as modulators of urinary stone formation. The urinary concentration of these modulators can be influenced by many metabolic disorders, that originate either in the nephron or other tissues (5,6).
The source of urinary oxalate is divided into endogenous and exogenous, e.g. dietary, whereas endogenous represents two thirds, and exogenous one third of the total urinary oxalate. Healthy individuals produce around 80-90% of their oxalate endogenously, as a metabolic product in the degradation of glycine, glyoxylate and ascorbic acid in the liver (7,8). Contrary to that, findings from Holmes et al. suggest that approximately half of urinary oxalate should be derived from the diet (9). Based on these data it is clear that exact numbers are hard to determine and further research will be needed.
In a normal western diet, the oxalate content was estimated to approximately 80-120 mg per day (0,89 mmol - 1,33 mmol) (10). According to different authors, it is estimated that only around 6-14% of the digested oxalate is normally absorbed through the intestinal tract (8,10–12). However, Liebman et al. showed that a dietary oxalate intake, greater than 180 mg per day (2 mmol per day) could lead to a higher absorption of oxalate, extending to values reaching 50% of digested oxalate being absorbed (13).

Oxalate absorption and its modulation


Most of the ingested oxalate binds in the intestinal tract to calcium, if available, or it is degraded by oxalate degrading bacteria (14). Thus as already stated above, only small amounts of dietary oxalate are absorbed from the intestinal tract. It appears that the absorption of oxalate occurs in 50% along the small intestine and another 50% in the large intestine (15).
The amount of ingested oxalate that has been absorbed in the intestinal tract and then entered the circulation is difficult to measure directly. This is the reason, why most of the researches measure the absorbed oxalate with an indirect method, through the amount of oxalate, being excreted in the urine. This way of measuring can be seen as valid, if significant amounts of the absorbed oxalate are not taken up by tissues, are not metabolized in the body, or are not secreted back into the intestine or other fluids such as sweat (11). As these assumptions appear to be valid in healthy individuals, there are growing evidence supporting a theory, that significant amount of circulating oxalate may be secreted back into the large intestine in some pathological conditions, such as hyperoxalemia or renal dysfunction (16). Recently, Voss et al. compared oxalate absorption between 120 healthy volunteers and 120 recurrent calcium oxalate stone formers on controlled diets. The study showed a significant higher oxalate absorption in stone formers. Furthermore, it showed that a small number of stone formers absorbed more than 20% of the oxalate load (17). Also Hesse et al. found differences in oxalate absorption reviewing several studies. They compared healthy individuals and patients with kidney stones and found evidence, which indicates that stone formers may on average absorb up to 50% more oxalate than healthy individuals (18). One of the possible explanations for such differences in absorption could have a genetic basis. It has been suggested that anion exchange proteins from the SLC26 family, and especially SLC26A6, play an important role not only in renal but also in small intestine oxalate transport (19,20).
An also important aspect is how ingested oxalate influences its excretion. Holmes et al. found out that apparently there is a much higher absorption of oxalate at low oxalate intakes then at high intakes. In their opinion the reason for this curvilinear relationship is that a much higher proportion of ingested oxalate is being ionized and available for absorption at low oxalate intakes. On the other hand at high oxalate intakes, a large fraction of oxalate will form complexes or get crystallized, thus unavailable for absorption. Based on these findings, the authors suggest, that on average, around 50% of the urinary oxalate excreted has its dietary origins, but this percentage may vary regarding different amounts of calcium and oxalate being ingested (9).
As already mentioned before, there are factors that can modulate the absorption of oxalate from the intestine. These include the co-ingestion of calcium and magnesium and the presence of oxalate degrading bacteria. Curhan et al. preformed a large prospective study on 45,619 men, 40 to 75 years old, who had no history of kidney stones. While observing the correlation between dietary calcium intake and the risk of symptomatic kidney stones, they have come to the conclusion that an inverse relationship between calcium intake and stone formation exists (21). They also suggested that the responsible mechanism for this effect was due to calcium biding to oxalate, thus reducing its availability for absorption. These findings were confirmed by other studies as well (13,18). Curhan et al. also performed another prospective study among 96,245 female participants, aged 27 to 44 years, with no history of kidney stones. For 8 years they were examining the association between dietary factors and the risk of incident symptomatic kidney stones. They confirmed the assumption that a higher intake of dietary calcium decreases the risk of kidney stone formation (22).
The other important factor influencing the absorption modulation is presence of oxalate degrading bacteria in the intestinal tract, which may lower the amount of oxalate available for absorption by utilizing it for their metabolically needs. Research has been mostly focus on Oxalobacter formigenes. A study performed by Troxel et al. linked the absence of oxalobacter colonization with increased urinary oxalate excretion in patients with kidney stone disease (23), and another two studies linked the absence of oxalobacter colonization with increased stone formation (24,25).
An increase in absorption of oxalate has also been associated with chronic inflammatory bowel diseases and intestinal resections. Normally the ingested calcium forms complexes with oxalate and consequently makes it unavailable for absorption. In these patients, calcium is bound to malabsorbed fatty acids instead to oxalate, thus more oxalate remains unbound and available for absorption (26). Another condition, leading to increased absorption of oxalate from the intestinal tract, is the deficiency or complete absence of intestinal oxalate degrading bacteria. Normally these bacteria would degrade approximately 50-80% of the dietary oxalate into carbon dioxide and formate, but in their absence or diminished number, more oxalate is available for absorption and consequently more oxalate is being excreted through urine (14).

Oxalate excretion


The kidneys excrete almost the entire oxalate, absorbed from the gastrointestinal tract. In the kidney, oxalate is freely filtered through glomeruli, followed by partial passive back-diffusion into peritubular capillaries, from where the residual oxalate is excreted by active tubular transport back into the lumen. The ratio between oxalate clearance and glomerular filtration rate is around 1,2, which implies the importance of tubular secretion of oxalate (11).
The proposed mechanism of oxalate secretion has been observed in a number of species, including humans. The oxalate secretion process in rat kidneys occurs in the proximal tubule, where also secretory pathways for other ions take place. Therefore it has been proposed, that the human oxalate secretory pathway occurs there as well. Although the transport processes and individual steps of the oxalate secretory pathway are still not fully understood, it has been suggested that anion exchange proteins from the SLC26 family are involved in this process. It is believed, that oxalate is directly removed from the blood as it flows through the kidneys, supposedly by a member of SLC26 family, sat-1 (SLC26A1) exchanger, which has been identified on the basolateral membrane of the proximal tubule cells. It exchanges oxalate for either sulfate or bicarbonate, thus acting as an oxalate transporter, which transfers oxalate from blood into the tubular cells. Following transcellular flux, oxalate is then released into the nephron lumen and excreted through urine. Among SLC26 exchangers family, A6, A7, A8 and A9 exchangers have been identified on the plasma membrane of the cells that can transport oxalate. Especially SLC26A6 is believed to play a role in secreting oxalate from the proximal tubule into urine, since it has been localized in the luminal membrane of proximal tubular cells (27–31).
After an oxalate rich meal, kidneys tend to secrete oxalate for an extended period of time. A study performed by Knight et al. compared intestinal and renal handling of oxalate loads in normal individuals and stone formers. Results showed that plasma oxalate levels, urinary oxalate excretion, and clearance ratio all increase similarly with increasing doses of oxalate in both, stone formers and control group. The same study also showed that renal oxalate secretion was evident up to 8 hours after a single oxalate load (4). Although several authors reported that high oxalate loads in animal models led to cell injury, detected through elevated urinary enzyme markers, that imply damage to renal tubular epithelial cells, there has been a lack in evidence for oxalate-induced tubular damage in humans (32).
A study, performed on healthy individuals, ingesting large doses of oxalate (up to 8 mmol or 720 mg), showed no increase in oxidative stress or renal injury markers, thus calling into question the importance of oxalate-induced cell membrane damage in calcium oxalate stone formation (11). Also another study, performed by Knight et al. showed no difference in excretion of oxidative stress or renal injury markers, even after highest oxalate loads in healthy subjects as well as in stone formers (4). The authors conclude that transient exposure of kidneys to high levels of oxalate may not be overtly harmful, however renal damage cannot be ruled out in more chronic exposures, like it was reported by others in animal model systems (4,5,33).

Hyperoxaluria and its treatment


Hyperoxaluria is one of the risk factors for developing kidney stone disease and is described as urinary excretion of more than 40 mg (0,44 mmol) of oxalate per day. It is associated with higher urinary saturation of calcium oxalate, which consequently promotes formation of calcium oxalate stones. Causes of hyperoxaluria can be divided into three categories: (a) primary hyperoxaluria, a rare autosomal recessive disorder in glyoxylate metabolism, (b) enteric hyperoxaluria, which is associated with chronic diarrheal states and intestinal malabsorptive states, accompanying inflammatory bowel disease, celiac sprue or intestinal resection, and (c) dietary hyperoxaluria, which follows an excessive dietary oxalate intake or high substrate levels, such as ascorbic acid (32).
Laminski et al. suggest that hyperoxaluria is present in approximately 20 to 40% of stone formers, thus making it an important risk factor for developing kidney stone disease. They also identified that if we rule out primary hyperoxaluria as a source of urinary oxalate, the reason for increased oxalate urinary levels could be either increased dietary oxalate intake, increased endogenous production by metabolism or increased enteral oxalate absorption (34).
Specific treatment options for hyperoxaluria are rather limited. Treatments are mostly limited to dietary restrictions and may not be appropriate for people, who have difficulties in defining causative dietary constituents in their own diet (35). Typical treatment strategies include: (a) dietary oxalate restriction to limit its delivery to the colon, (b) low fat diets to limit malabsorption and effects of fatty and bile acids describe above, (c) oral calcium administration to bind oxalate and form complexes with it, and (d) bile acids sequestrants like cholestyramine (8). In addition to that it is possible to administer some drugs like thiazide diuretics, potassium citrate, cellulose phosphate or pyridoxine, which are all more or less successful in lowering the urinary oxalate (36). It has been also tried to degrade oxalate present in diet with help of an enzyme, called oxalate oxidase, but it is rather difficult to achieve satisfying results as these enzymes are likely to be inactivated by proteolytic enzymes during its passage through the gastrointestinal tract (37). Recently it has been proposed, that it would be possible to treat hyperoxaluria with oxalate degrading bacteria, since these bacteria have been identified in human feces (38). Usually, oxalate degrading bacteria colonize our intestinal tract and use the ingested oxalate as a source of energy. As such, they are representatives of normal microflora in our intestine and could serve as a natural defense mechanism against urolithiasis (14).

Conclusion


Oxalate plays an important role in kidney stone formation, since calcium oxalate composites approximately 80% of all kidney stones. Understanding oxalate absorption, its modulation and oxalate excretion is important in developing therapeutical approaches in treatment of kidney stone disease. Although genetic and biochemical research on oxalate absorption and excretion has already revealed some of the important underlying pathways, the biochemical processes of different oxalate pathways and its influence on stone formation need further research, to fully understand this molecule, which is responsible for the formation of the majority of kidney stones.

References


1. Pak CY. Kidney stones. The Lancet. 1998 jun 13;351(9118):1797–801.
2. Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int. 2003 maj;63(5):1817–23.
3. Coe FL, Parks JH, Asplin JR. The pathogenesis and treatment of kidney stones. N. Engl. J. Med. 1992 okt 15;327(16):1141–52.
4. Knight J, Holmes RP, Assimos DG. Intestinal and renal handling of oxalate loads in normal individuals and stone formers. Urol Res. 2007 apr;35(3):111–7.
5. Khan SR. Renal tubular damage/dysfunction: key to the formation of kidney stones. Urol Res. 2006 jan;34(2):86–91.
6. Khan SR, Kok DJ. Modulators of urinary stone formation. Front. Biosci. 2004 maj 1;9:1450–82.
7. Balaji KC, Menon M. Mechanism of stone formation. Urol. Clin. North Am. 1997 feb;24(1):1–11.
8. Lieske JC, Goldfarb DS, De Simone C, Regnier C. Use of a probiotic to decrease enteric hyperoxaluria. Kidney Int. 2005 sep;68(3):1244–9.
9. Holmes RP, Goodman HO, Assimos DG. Contribution of dietary oxalate to urinary oxalate excretion. Kidney Int. 2001 jan;59(1):270–6.
10. Siener R, Hesse A. The effect of different diets on urine composition and the risk of calcium oxalate crystallisation in healthy subjects. Eur. Urol. 2002 sep;42(3):289–96.
11. Holmes RP, Assimos DG. The impact of dietary oxalate on kidney stone formation. Urol Res. 2004 jun;32(5):311–6.
12. von Unruh GE, Voss S, Sauerbruch T, Hesse A. Reference range for gastrointestinal oxalate absorption measured with a standardized [13C2]oxalate absorption test. J. Urol. 2003 feb;169(2):687–90.
13. Liebman M, Costa G. Effects of calcium and magnesium on urinary oxalate excretion after oxalate loads. J. Urol. 2000 maj;163(5):1565–9.
14. Hoppe B, Unruh G, Laube N, Hesse A, Sidhu H. Oxalate degrading bacteria: new treatment option for patients with primary and secondary hyperoxaluria Urol Res. 2005 nov;33(5):372–5.
15. Holmes RP, Goodman HO, Assimos DG. Dietary oxalate and its intestinal absorption. Scanning Microsc. 1995;9(4):1109–18; discussion 1118–20.
16. Hatch M, Freel RW, Vaziri ND. Regulatory aspects of oxalate secretion in enteric oxalate elimination. J. Am. Soc. Nephrol. 1999 nov;10 Suppl 14:S324–8.
17. Voss S, Hesse A, Zimmermann DJ, Sauerbruch T, von Unruh GE. Intestinal oxalate absorption is higher in idiopathic calcium oxalate stone formers than in healthy controls: measurements with the [(13)C2]oxalate absorption test. J. Urol. 2006 maj;175(5):1711–5.
18. Hesse A, Schneeberger W, Engfeld S, Von Unruh GE, Sauerbruch T. Intestinal hyperabsorption of oxalate in calcium oxalate stone formers: application of a new test with [13C2]oxalate. J. Am. Soc. Nephrol. 1999 nov;10 Suppl 14:S329–33.
19. Holmes RP, Assimos DG, Goodman HO. Genetic and dietary influences on urinary oxalate excretion. Urol. Res. 1998;26(3):195–200.
20. Mount DB, Romero MF. The SLC26 gene family of multifunctional anion exchangers. Pflugers Arch. 2004 feb;447(5):710–21.
21. Curhan GC, Willett WC, Rimm EB, Stampfer MJ. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N. Engl. J. Med. 1993 mar 25;328(12):833–8.
22. Curhan GC, Willett WC, Knight EL, Stampfer MJ. Dietary factors and the risk of incident kidney stones in younger women: Nurses’ Health Study II. Arch. Intern. Med. 2004 apr 26;164(8):885–91.
23. Troxel SA, Sidhu H, Kaul P, Low RK. Intestinal Oxalobacter formigenes colonization in calcium oxalate stone formers and its relation to urinary oxalate. J. Endourol. 2003 apr;17(3):173–6.
24. Mikami K, Akakura K, Takei K, Ueda T, Mizoguchi K, Noda M, idr. Association of absence of intestinal oxalate degrading bacteria with urinary calcium oxalate stone formation. Int. J. Urol. 2003 jun;10(6):293–6.
25. Sidhu H, Schmidt ME, Cornelius JG, Thamilselvan S, Khan SR, Hesse A, idr. Direct correlation between hyperoxaluria/oxalate stone disease and the absence of the gastrointestinal tract-dwelling bacterium Oxalobacter formigenes: possible prevention by gut recolonization or enzyme replacement therapy. J. Am. Soc. Nephrol. 1999 nov;10 Suppl 14:S334–40.
26. Hoppe B, Leumann E, von Unruh G, Laube N, Hesse A. Diagnostic and therapeutic approaches in patients with secondary hyperoxaluria. Front. Biosci. 2003 sep 1;8:e437–43.
27. Tremaine LM, Bird JE, Quebbemann AJ. Renal tubular excretory transport of oxalate in the chicken. J. Pharmacol. Exp. Ther. 1985 apr;233(1):7–11.
28. Knight TF, Sansom SC, Senekjian HO, Weinman EJ. Oxalate secretion in the rat proximal tubule. Am. J. Physiol. 1981 apr;240(4):F295–8.
29. Karniski LP, Lötscher M, Fucentese M, Hilfiker H, Biber J, Murer H. Immunolocalization of sat-1 sulfate/oxalate/bicarbonate anion exchanger in the rat kidney. Am. J. Physiol. 1998 jul;275(1 Pt 2):F79–87.
30. Jiang Z, Grichtchenko II, Boron WF, Aronson PS. Specificity of anion exchange mediated by mouse Slc26a6. J. Biol. Chem. 2002 sep 13;277(37):33963–7.
31. Knauf F, Yang CL, Thomson RB, Mentone SA, Giebisch G, Aronson PS. Identification of a chloride-formate exchanger expressed on the brush border membrane of renal proximal tubule cells. Proc. Natl. Acad. Sci. U.S.A. 2001 jul 31;98(16):9425–30.
32. Campbell M. Campbell-Walsh urology   editor-in-chief, Alan J. Wein   editors, Louis R. Kavoussi ... [et al.]. 9th iz. Philadelphia: W.B. Saunders; 2007.  1361-1564 p.
33. Jonassen JA, Cao L-C, Honeyman T, Scheid CR. Mechanisms mediating oxalate-induced alterations in renal cell functions. Crit. Rev. Eukaryot. Gene Expr. 2003;13(1):55–72.
34. Laminski NA, Meyers AM, Kruger M, Sonnekus MI, Margolius LP. Hyperoxaluria in patients with recurrent calcium oxalate calculi: dietary and other risk factors. Br J Urol. 1991 nov;68(5):454–8.
35. Goldfarb DS, Modersitzki F, Asplin JR. A randomized, controlled trial of lactic acid bacteria for idiopathic hyperoxaluria. Clin J Am Soc Nephrol. 2007 jul;2(4):745–9.
36. Campieri C, Campieri M, Bertuzzi V, Swennen E, Matteuzzi D, Stefoni S, idr. Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration. Kidney Int. 2001 sep;60(3):1097–105.
37. Ramakrishnan V, Lathika KM, D’Souza SJ, Singh BB, Raghavan KG. Investigation with chitosan-oxalate oxidase-catalase conjugate for degrading oxalate from hyperoxaluric rat chyme. Indian J. Biochem. Biophys. 1997 avg;34(4):373–8.
38. Kodama T, Akakura K, Mikami K, Ito H. Detection and identification of oxalate degrading bacteria in human feces. International Journal of Urology. 2002 jul 1;9(7):392–7.

Source(s) of Funding


None

Competing Interests


None

Disclaimer


This article has been downloaded from WebmedCentral. With our unique author driven post publication peer review, contents posted on this web portal do not undergo any prepublication peer or editorial review. It is completely the responsibility of the authors to ensure not only scientific and ethical standards of the manuscript but also its grammatical accuracy. Authors must ensure that they obtain all the necessary permissions before submitting any information that requires obtaining a consent or approval from a third party. Authors should also ensure not to submit any information which they do not have the copyright of or of which they have transferred the copyrights to a third party.
Contents on WebmedCentral are purely for biomedical researchers and scientists. They are not meant to cater to the needs of an individual patient. The web portal or any content(s) therein is neither designed to support, nor replace, the relationship that exists between a patient/site visitor and his/her physician. Your use of the WebmedCentral site and its contents is entirely at your own risk. We do not take any responsibility for any harm that you may suffer or inflict on a third person by following the contents of this website.

Reviews
3 reviews posted so far

A concise review of a promising research field
Posted by Dr. Tomislav Sarenac on 19 Feb 2012 11:01:53 AM GMT

A very concise review of a relevant subject
Posted by Mr. Aljaz Majer on 06 Feb 2012 05:37:43 PM GMT

Nice article with quite a lot of literature reviewed
Posted by Dr. Robi Kelc on 16 Jan 2012 07:49:39 AM GMT

Comments
0 comments posted so far

Please use this functionality to flag objectionable, inappropriate, inaccurate, and offensive content to WebmedCentral Team and the authors.

 

Author Comments
0 comments posted so far

 

WebmedCentral Article: The Role Of Oxalate In Urolithiasis

What is article Popularity?

Article popularity is calculated by considering the scores: age of the article
Popularity = (P - 1) / (T + 2)^1.5
Where
P : points is the sum of individual scores, which includes article Views, Downloads, Reviews, Comments and their weightage

Scores   Weightage
Views Points X 1
Download Points X 2
Comment Points X 5
Review Points X 10
Points= sum(Views Points + Download Points + Comment Points + Review Points)
T : time since submission in hours.
P is subtracted by 1 to negate submitter's vote.
Age factor is (time since submission in hours plus two) to the power of 1.5.factor.

How Article Quality Works?

For each article Authors/Readers, Reviewers and WMC Editors can review/rate the articles. These ratings are used to determine Feedback Scores.

In most cases, article receive ratings in the range of 0 to 10. We calculate average of all the ratings and consider it as article quality.

Quality=Average(Authors/Readers Ratings + Reviewers Ratings + WMC Editor Ratings)